Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Britain

Brexit: the facts (and the alternative facts)

How Brexit affects pharma

- PMLiVE

Brexit: Implications for the pharma industry

From patents to the EMA, data protection to clinical trials, there's a lot that should be a concern

Can UK pharma rise to the post-Brexit challenge?

Our dominant and thriving industry is one we should be proud of

- PMLiVE

Boehringer Ingelheim calls for “strong and united” Europe

Simone Menne highlights the EU's achievements, and her firm's contribution

- PMLiVE

Connecting the dots

What happens ‘here’ impacts what happens ‘there’

- PMLiVE

UK pharma strikes optimistic note as Brexit process begins

Says life science industry is accustomed to ‘uncertainty’ and can thrive in a post-EU Britain

- PMLiVE

Brexit begins as UK PM signs letter triggering Article 50

Theresa May sets wheels in motion as Britain awaits EU response

UK flag

ABPI delivers wish-list to Hammond ahead of spring budget

Pharma industry has three key requests

- PMLiVE

Bayer: Post-truth politics severely handicaps innovation

And firm also voices its concerns over Brexit

- PMLiVE

J&J gets CHMP backing for broader Darzalex use

Recommendation for earlier-stage approval could see multiple myeloma drug reach blockbuster sales

- PMLiVE

AZ nears EU approval for hyperkalaemia drug Lokelma

CHMP adopts positive opinion for the potassium-binding treatment

- PMLiVE

Mundipharma to launch first MabThera biosimilar in EU

EMA approves Truxima in all indications licensed to Roche’s cancer drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links